Search
for

    Did you mean BRAVE-AA1?
    Glossary BRAVE-AA1

    clinical trial for baricitinib treating alopecia areata

    BRAVE-AA1 is a clinical trial designed to evaluate the efficacy and safety of a medication called baricitinib for treating alopecia areata, an autoimmune condition that causes hair loss. The trial aims to determine how well baricitinib, a Janus kinase (JAK) inhibitor, can help regrow hair in individuals with this condition.

    Related Terms

    Research 10 of 1000+

    1. 27604 Response to baricitinib in the treatment of patients with early and late onset alopecia areata in the phase 2 portion of BRAVE-AA1 randomized controlled trial Journal of The American Academy of Dermatology · 2021 · 1 citations
    2. 26143 Time to scalp hair, eyebrow, and eyelash improvement in patients with alopecia areata treated with baricitinib in the phase 2 portion of the phase 2/3 BRAVE-AA1 study Journal of The American Academy of Dermatology · 2021 · 1 citations
    3. 49690 Long-term efficacy of baricitinib in alopecia areata: 3-year results from BRAVE-AA1 and BRAVE-AA2 Journal of the American Academy of Dermatology · 2024
    4. Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2) American Journal of Clinical Dermatology · 2023 · 20 citations
    5. Efficacy of Baricitinib in Patients with Various Degrees of Alopecia Areata Severity: Post-Hoc Analysis from BRAVE AA1 and BRAVE AA2 Dermatology and Therapy · 2023 · 1 citations
    6. Clinical evidence for JAK inhibition in alopecia areata: A comprehensive review 2026
    7. How Long to Treat to Achieve Desired Treatment Outcomes with Baricitinib 4 mg in Severe Alopecia Areata: Evidence-based Approach Dermatology and Therapy · 2026
    8. Concordance between clinician-reported and patient-reported outcomes of eyebrow and eyelash hair loss in patients with severe alopecia areata: Results from BRAVE-AA1 and BRAVE-AA2 studies Journal of the American Academy of Dermatology · 2024 · 2 citations
    9. Efficacité à long terme du baricitinib dans le traitement de la pelade : résultats à la semaine 104 des études BRAVE-AA1 et BRAVE-AA2 Annales de dermatologie et de vénéréologie, FMC · 2023
    10. Characterization of scalp, eyelash and eyebrow hair regrowth in patients with severe alopecia areata randomized to placebo in brave AA1 and brave AA2 trials JEADV Clinical Practice · 2024
    All research results →

    Learn 1

    1. Baricitinib JAK inhibitor pill used for severe alopecia areata

    Community

    — no results

    Try a deeper search in community →